Glaxo, HGS Begin Study of Lupus Drug
Posted on: Tuesday, 13 February 2007, 12:01 CST
U.S. biotech firm Human Genome Sciences and British drug giant GlaxoSmithKline said they've begun a trial of LymphoStat-B for Lupus.
The companies said dosing has begun in the trial dubbed BLISS-76, one of a pair of phase 3 trials of the new treatment in patients with active systemic lupus erythematosus (SLE).
The two multi-center, phase 3 superiority trials will evaluate LymphoStat-B plus standard of care versus placebo plus standard of care.
The first study, BLISS-76, will last 76 weeks, with data analyzed after 52 weeks in support of a potential filing for approval by the Food and Drug Administration.
The second trial, BLISS-52, will last 52 weeks and is expected to begin in the first half of 2007, the companies said.
We believe that LymphoStat-B could address the significant medical need of patients suffering from SLE, and advancing this novel therapeutic antibody to phase 3 clinical trials is a major step toward that goal, said H. Thomas Watkins, HGS's president and chief executive officer.
The companies entered into a development deal on LymphoStat-B in August 2006.
Source: United Press International
Related Articles
- Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
- Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
- Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
- The GI Company to Present Phase I &Amp; II Oral Mucositis Data at MASCC / ISOO Annual Meeting
- The GI Company to Present Phase II Oral Mucositis Data at ASCO Annual Meeting
- Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
- Targeted Genetics Initiates Phase I Trial for Childhood Blindness
- Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
- The Medicines Company Completes Clevidipine Phase III Safety Trials and Initiates Phase III Severe Hypertension Trial; ECLIPSE Enrollment Complete, First Patient Enrolled in VELOCITY
- 2005 Healthy BET Fitness Challenge Finalists Begin 12-Week Challenge Phase
 |
 |
User Comments (0)
RSS Feeds